$180M Boost for Celea Therapeutics as It Preps Phase 3 IPF Trial
Event summary
- $180M financing secured for Celea Therapeutics, backed by RA Capital Management and Leaps by Bayer.
- PureTech Health retains 35.4% stake in Celea post-financing, with $70M reserved for future support.
- Phase 3 SURPASS-IPF trial of deupirfenidone set to begin Q3 2026, aiming to challenge existing IPF treatments.
The big picture
This financing positions Celea to challenge the IPF treatment landscape with a head-to-head Phase 3 trial, while PureTech shifts to a leaner model. The $180M round reflects growing investor interest in next-generation antifibrotics amid limited IPF therapy options.
What we're watching
- Trial Execution
- Whether Celea can successfully execute the Phase 3 SURPASS-IPF trial and demonstrate deupirfenidone's superiority over pirfenidone.
- Commercial Potential
- The pace at which deupirfenidone could become a new standard of care for IPF, given the limited treatment options currently available.
- Investor Confidence
- How the $180M financing and PureTech's strategic pivot will impact investor confidence in Celea's long-term prospects.
Related topics